Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab
International Forum of Allergy & Rhinology · 25.10.2026
DOI: 10.1002/alr.70303 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, online erschienen am 25.10.2026. Verfasst von Emeline Delaunay und 6 weiteren Autor:innen. Beteiligte Einrichtung: U1286 - INFINITE - Institute for Translational Research in Inflammation, INSERM, CHU Lille, Univ. Lille, Lille, France. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Medical Center of Lille, France, Inserm unit INFINITE_U1286, Lille, France.
Abstract (Originalsprache)
This was a Phase IV observational cohort study conducted at Lille University Hospital.Patients with severe CRSwNP were included before treatment with dupilumab, and data were collected at base- Key Points• Blood eosinophils show increased CCR3 expression in patients with CRSwNP and associated asthma.• Dupilumab treatment progressively lowers CCR3 expression on blood eosinophils, ultimately restoring levels similar to those observed in healthy controls.• Higher baseline CCR3 expression on blood eosinophils is associated with better ETOC.I scores after 18 months of treatment.line (M0) and at 3 (M3), 6 (M6), 12 (M12), and 18 months (M18) post-treatment (Figure S1 ).The study adhered to the Declaration of Helsinki, the French Public Health Code, and European Union Good Clinical Practice guidelines.Written informed consent was obtained from all participants.The protocol was approved by the French Committee for the Protection of Individuals and registered at ClinicalTrials.gov(NCT05228041).Non-asthmatic, nonsmoking, and non-allergic healthy controls were also included, as provided by the PLEIAD protocol (NCT04187976).Clinical response was determined at each time point and evaluated using the Sino-Nasal Outcome Test-22 (SNOT-22) quality of life questionnaire (0-110) and visual analogue scales (VAS) for individual nasal symptoms (nasal obstruction, dysosmia) and for
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- U1286 - INFINITE - Institute for Translational Research in Inflammation, INSERM, CHU Lille, Univ. Lille, Lille, France.
- Médecine Interne et Immunologie Clinique, Institut D'immunologie, CHU Lille, Lille, France.
- Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Service d'Otorhinolaryngologie, CHU Lille, Univ. Lille, Lille, France.
ORCID-Profile: Emeline Delaunay, Geoffrey Mortuaire
Förderung
- University Medical Center of Lille, France
- Inserm unit INFINITE_U1286, Lille, France
Zitieren
APA
Delaunay, E., Esnault, S., Dendooven, A., Trauet, J., Desvant, C., Lefèvre, G., & Mortuaire, G. (2026). Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.70303
Vancouver
Delaunay E, Esnault S, Dendooven A, Trauet J, Desvant C, Lefèvre G, et al. Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab. International Forum of Allergy & Rhinology. 2026. doi:10.1002/alr.70303
BibTeX
@article{Delaunay2026,
author = {Delaunay, Emeline and Esnault, Stephane and Dendooven, Arnaud and Trauet, Jacques and Desvant, Céline and Lefèvre, Guillaume and Mortuaire, Geoffrey},
title = {Blood Eosinophils From CRSwNP Patients Present Higher CCR3 Expression Associated With Olfactory Recovery After Treatment With Dupilumab},
journal = {International Forum of Allergy & Rhinology},
year = {2026},
doi = {10.1002/alr.70303}
}
EUVIMED